C-KQUGIstesso
mitochondrial Complex I modulators, oral small molecules, tissue repair
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-KQUG
C-KQUGC-KQUGmitochondrial Complex I modulators, oral small molecules, tissue repair
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Istesso mitochondrial Complex I modulators, oral small molecules, tissue repair
Istesso is developing oral regenerative medicines for chronic disease and age-related decline. Its approach centers on mitochondrial Complex I modulators, a class of oral small molecule drugs intended to repair and regenerate tissue across multiple organs and disease settings. Its lead clinical program, leramistat, is in Phase 2 trials, including sarcopenia.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Istesso — Translational · Bottom quartile. Derived deterministically from 2 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic